Brain radiotherapy added to first-line immunochemotherapy improves survival in patients with treatment-naïve, driver-negative lung adenocarcinoma and synchronous brain metastases

Read full text Summarise with VIRAT
Authors: Rui Wang, Jianxi Zhou, Li Xiao, Hongling Lu, Yaru Kong, Yongchao Yu, Yunchuan Sun, Jiaju Zhang, Yingnan Zhou
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: The optimal integration of brain radiotherapy with first-line immunochemotherapy for treatment-naïve, driver-negative lung adenocarcinoma patients with synchronous brain metastases remains unclear. This study assessed the efficacy and safety of this combined strategy. Methodology: In this retrospective cohort, 172 eligible patients were divided into two groups: the Combination group (immunochemotherapy plus brain radiotherapy, n=86) and the Systemic therapy group (immunochemotherapy alone, n=86). The primary endpoint was overall survival (OS); secondary endpoints included intracranial progression-free survival (iPFS), progression-free survival (PFS), intracranial/extracranial objective response rates (iORR/eORR) and safety. Results: After a median follow-up of 36.5 months, the Combination group showed significantly longer median OS (23.5 vs. 17.5 months; HR = 0.729, 95%CI:0.538-0.988, P = 0.036) and iPFS (13.6 vs. 7.7 months; HR = 0.699, 95%CI:0.515-0.947, P = 0.017), while unadjusted PFS showed no statistical difference (P = 0.245). iORR was higher in the Combination group (66.3% vs. 46.5%, P = 0.009), with comparable eORR between groups. Multivariate analysis verified brain radiotherapy as an independent favorable factor for OS and iPFS, with consistent benefits across subgroups. Safety profiles were manageable, with no elevated severe immune-related toxicities. Conclusion: For this patient population, adding brain radiotherapy to first-line immunochemotherapy significantly improves OS and intracranial disease control, without impairing systemic efficacy or increasing severe toxicity, supporting its clinical consideration.

Fields of Study & Subjects

Brain Metastases and Treatment Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Frontiers in Oncology
Volume
16
Pages
1808429–1808429
Publication date
26 March 2026
Language
EN